In a major advancement for cholesterol treatment, the US Food and Drug Administration (FDA) has approved Lipfendra (enlicitide), the world’s first once-daily oral PCSK9 inhibitor. Developed by Merck, the medication offers a convenient alternative for adults with certain types of high cholesterol who require additional LDL (“bad”) cholesterol reduction despite taking statins.
Unlike existing PCSK9 inhibitors that are administered through injections, Lipfendra is available as a daily tablet, making cholesterol management easier for eligible patients.
What Is Lipfendra?
Lipfendra is a prescription medicine designed to lower low-density lipoprotein (LDL) cholesterol, commonly referred to as bad cholesterol. It belongs to the PCSK9 inhibitor class of drugs, which help the body eliminate excess cholesterol more effectively.
The medication has been approved as an add-on treatment, meaning it is intended to be used alongside lifestyle changes and other cholesterol-lowering medicines rather than replacing them.
How Does Lipfendra Work?
The liver naturally removes LDL cholesterol from the bloodstream through special proteins known as LDL receptors. However, another protein called PCSK9 breaks down these receptors, reducing the liver’s ability to clear cholesterol efficiently.
Lipfendra blocks the PCSK9 protein, allowing more LDL receptors to remain active. As a result, the liver can remove larger amounts of LDL cholesterol from the blood, helping reduce overall cholesterol levels.
Unlike statins, which lower the body’s cholesterol production, Lipfendra enhances the body’s natural cholesterol-clearing process.
How Is Lipfendra Different From Statins?
Statins remain the standard first-line treatment for high cholesterol and work effectively for most patients. However, some individuals continue to have elevated LDL cholesterol even after taking the highest tolerated dose.
Lipfendra is designed for those patients who need additional cholesterol reduction.
Previously, doctors often prescribed injectable PCSK9 inhibitors such as Repatha or Praluent in these cases. Lipfendra now provides a convenient oral alternative, eliminating the need for regular injections.
Who Is Eligible for Lipfendra?
The FDA has approved Lipfendra for adults who need additional LDL cholesterol reduction despite existing treatment.
The medication may benefit people who:
- Continue to have high LDL cholesterol while taking statins.
- Have familial hypercholesterolemia, an inherited condition that causes extremely high cholesterol levels.
- Require greater cholesterol reduction to lower their cardiovascular risk.
- Prefer taking a daily tablet instead of injectable medications.
Doctors are unlikely to prescribe Lipfendra as the initial treatment for individuals with mildly elevated cholesterol levels.
Clinical Trial Results
According to data reviewed by the FDA, adding Lipfendra to ongoing statin therapy produced significant cholesterol reductions.
Late-stage clinical trials showed that the medicine lowered LDL cholesterol by approximately 56% to 60% when used alongside statins.
Researchers also reported that the medication was generally well tolerated.
The most commonly observed side effects included:
- Diarrhoea
- Dizziness
Importantly, the frequency of serious adverse events was comparable to that seen in patients receiving a placebo.
Why This FDA Approval Is Important
Heart disease remains one of the leading causes of death worldwide, and high LDL cholesterol is a major risk factor for cardiovascular complications.
One of the biggest challenges in long-term cholesterol management is ensuring patients consistently follow their treatment plans. Many individuals find injectable medications inconvenient or uncomfortable, which can affect adherence.
The approval of Lipfendra introduces a more convenient oral option that could improve treatment compliance and help more patients achieve recommended cholesterol targets.
What Happens Next?
While FDA approval represents an important milestone in cholesterol treatment, experts note that additional long-term studies will continue to evaluate how Lipfendra performs in reducing heart attacks, strokes, and other cardiovascular events compared with existing therapies.
As research progresses, the new once-daily pill could become a valuable addition to the growing range of treatments available for people living with high cholesterol and elevated heart disease risk.